News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
5/26/2010 9:36:00 AM
REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces new data from two studies using the Company’s miRview™ mets test to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP) will be presented in a poster session and in the abstract book at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting to be held at the McCormick Place Convention Center in Chicago from June 4-8, 2010.
Researchers from the University of Texas, M. D. Anderson Comprehensive Cancer Center, considered a leading tertiary referral hospital which handles some of the more challenging CUP cases, will hold a poster presentation to discuss an ongoing prospective study conducted in collaboration with Rosetta Genomics. In the study involving 90 tissue samples, miRview mets demonstrated high concordance with the clinical diagnosis determined by the clinicians at M. D. Anderson.
The poster entitled, “Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP)” will be presented at:
Session: Gastrointestinal (Noncolorectal) Cancer
Type: General Poster Session
Date/Time: Sunday, June 6, from 2:00 PM to 6:00 PM
Location: S Hall A2, Abstract #4153
Presented By: Gauri Varadhachary, MD, University of Texas, M. D. Anderson Comprehensive Cancer Center
“CUP represents a major diagnostic challenge for oncologists. Identification of the tissue-of-origin of metastatic tumors is vital for patient management, allowing physicians to guide the use of specific therapies, which may impact survival,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. “Through our collaboration with M. D. Anderson, we demonstrate miRview mets’ ability to assist clinicians in real-time to better manage and treat people with CUP. While M. D. Anderson houses some of the leading physicians in CUP, it is important to remember that most cancer centers do not have the same level of expertise. Our miRview mets test enables patients and physicians to benefit from the same high level of diagnostic accuracy as patients treated in the world’s leading CUP clinic, regardless of where they are in the world."
An additional study conducted with collaborators from the University of Heidelberg in Germany will be published as an abstract in the ASCO 2010 Annual Meeting abstract book, which will be available throughout the conference. This study, entitled “Accurate classification of metastatic brain tumors using a novel microRNA-based test,” validated the high accuracy of the miRview mets test in identifying the ToO of metastasis of unknown primary and demonstrated its clinical utility. The test was also able to suggest origins in cases where the pathological review was insufficient, suggesting additional clinical utility in those hard-to-resolve cases.
MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. MicroRNAs’ unique advantage as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19-21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. To learn more about microRNAs, please visit www.rosettagenomics.com.
About miRview™ Products
miRview™ are a series of microRNA-based diagnostic tests developed by Rosetta Genomics. miRview™ mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary (CUP) patients. miRview™ squamous accurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain targeted therapies. miRview™ meso diagnoses mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura. This test can be used to rule out mesothelioma in patients diagnosed with a tumor in the lung or pleura, who may have been exposed to asbestos in the past. miRview™ tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. The company’s tests are now being offered through distributors around the globe. For more information, please visit www.mirviewdx.com.
About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CAP accredited, CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journal’s Technology Innovation Awards in the medical/biotech category. To learn more, please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta’s approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosetta’s ability to obtain, maintain and protect its intellectual property; Rosetta’s ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta’s need and ability to obtain additional funding to support its business activities; Rosetta’s dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta’s ability to successfully develop its products and services; Rosetta’s ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta’s technology; competition from others using technology similar to Rosetta’s and others developing products for similar uses; Rosetta’s dependence on collaborators; and Rosetta’s short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.